This evidence synthesis has been compiled by members of the CITF Secretariat and does not necessarily represent the views of all CITF members.

By Mariana Bego 

Members of the Moderna COVID-19 mRNA vaccine study group recently released a short correspondence in the New England Journal of Medicine, highlighting the persistent antibody response after the first six months of receiving the second dose of this vaccine. High levels of antibody activity were observed in all age groups (18 to 55, 56 to 70, and over 71 years of age). Neutralizing antibodies were detected in all 33 participants but were lower in participants over the age of 55. Ongoing studies continue to monitor immune responses over time and are in the process of studying the effect of a booster dose to extend the duration and breadth of the immune response against emerging SARS-CoV-2 variants.


Read more:

Doria-Rose N, Suthar MS, Makowski M, O’Connell S, McDermott AB, Flach B, Ledgerwood JE, Mascola JR, Graham BS, Lin BC, O’Dell S, Schmidt SD, Widge AT, Edara VV, Anderson EJ, Lai L, Floyd K, Rouphael NG, Zarnitsyna V, Roberts PC, Makhene M, Buchanan W, Luke CJ, Beigel JH, Jackson LA, Neuzil KM, Bennett H, Leav B, Albert J, Kunwar P; mRNA-1273 Study Group. Antibody persistence through 6 Months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med. 2021 Jun 10;384(23):2259-2261. doi: 10.1056/NEJMc2103916.